Vicore Pharma
- Website
- vicorepharma.com
- Total Funding
- $48.0M
- Last Round
- $48.0M Venture RoundNov 2025
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Vicore Pharma is a clinical-stage biopharmaceutical company developing a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO.
Summary
Vicore Pharma is a Biotech company. It has raised $48.0M in total across 1 round, most recently a $48.0M Venture Round in Nov 2025. Investors include Invus and Capital Group.
Funding History
Nov 2025
Investors
Similar Companies
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/vicore-pharma"><img src="https://indexed.vc/api/badge/company/vicore-pharma" alt="Vicore Pharma on Indexed.vc" width="260" height="76" /></a>